Standout Papers

Resistant Hypertension: Diagnosis, Evaluation, and Treatment 2004 2026 2011 2018 1.6k
  1. Resistant Hypertension: Diagnosis, Evaluation, and Treatment (2008)
    David A. Calhoun, Daniel Jones et al. Circulation
  2. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure (2004)
    Anne L. Taylor, Susan Ziesche et al. New England Journal of Medicine
  3. Resistant Hypertension: Diagnosis, Evaluation, and Treatment (2008)
    David A. Calhoun, Daniel Jones et al. Hypertension
  4. Socioeconomic Status and Cardiovascular Outcomes (2018)
    William M. Schultz, Heval Mohamed Kelli et al. Circulation
  5. Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 (2011)
    Brent M. Egan, Yumin Zhao et al. Circulation
  6. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly (2011)
    Wilbert S. Aronow, Jerome L. Fleg et al. Circulation
  7. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis (2018)
    Sotirios Tsimikas, Sergio Fazio et al. Journal of the American College of Cardiology
  8. Zika virus pandemic—analysis of Facebook as a social media health information platform (2016)
    Megha Sharma, Kapil Yadav et al. American Journal of Infection Control
  9. Ten things to know about ten cardiovascular disease risk factors (2021)
    Harold Bays, Pam R. Taub et al. SHILAP Revista de lepidopterología
  10. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement (2022)
    Nathan D. Wong, Matthew J. Budoff et al. SHILAP Revista de lepidopterología
  11. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice (2024)
    Marlys L. Koschinsky, Archna Bajaj et al. Journal of clinical lipidology
  12. Social determinants of health and premature death among adults in the USA from 1999 to 2018: a national cohort study (2023)
    Joshua D. Bundy, Katherine T. Mills et al. The Lancet Public Health

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 88 standout
Sub-graph 1 of 14

Citing Papers

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
2025 Standout
Lipoprotein(a) and cardiovascular disease
2024 Standout
33 intermediate papers

Works of Keith C. Ferdinand being referenced

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
2024 Standout
Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials
2019
and 24 more

Author Peers

Author Last Decade Papers Cites
Keith C. Ferdinand 7722 2787 2302 259 12.5k
John M. Flack 8483 2940 2199 212 13.5k
Michael H. Alderman 8582 2545 1853 214 14.2k
Brent M. Egan 7318 3027 1593 277 12.9k
Lee A. Green 7703 2375 1711 117 13.5k
Barry J. Materson 9648 3496 1637 106 14.7k
Joseph L. Izzo 11074 4028 2134 186 17.6k
John W. McEvoy 7459 3005 4123 254 15.7k
Renata Cífková 7627 2444 1749 209 11.9k
Michel Burnier 7065 3399 1730 598 16.5k
Barry L. Carter 6157 2010 1148 150 10.7k

All Works

Loading papers...

Rankless by CCL
2026